Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Seres Therapeutics (MCRB) over the last 10 years, with Q3 2025 value amounting to $2.8 million.

  • Seres Therapeutics' Other Non Operating Income rose 11261.71% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.3 million, marking a year-over-year increase of 20544.21%. This contributed to the annual value of -$14.1 million for FY2024, which is 1062761.19% down from last year.
  • Latest data reveals that Seres Therapeutics reported Other Non Operating Income of $2.8 million as of Q3 2025, which was up 11261.71% from $4.3 million recorded in Q2 2025.
  • Over the past 5 years, Seres Therapeutics' Other Non Operating Income peaked at $7.1 million during Q1 2025, and registered a low of -$22.5 million during Q3 2024.
  • Moreover, its 5-year median value for Other Non Operating Income was -$23000.0 (2022), whereas its average is -$44789.5.
  • Its Other Non Operating Income has fluctuated over the past 5 years, first surged by 312727.27% in 2023, then plummeted by 235395.4% in 2024.
  • Over the past 5 years, Seres Therapeutics' Other Non Operating Income (Quarter) stood at -$316000.0 in 2021, then surged by 92.72% to -$23000.0 in 2022, then soared by 1560.87% to $336000.0 in 2023, then soared by 2006.25% to $7.1 million in 2024, then crashed by 59.86% to $2.8 million in 2025.
  • Its Other Non Operating Income stands at $2.8 million for Q3 2025, versus $4.3 million for Q2 2025 and $7.1 million for Q1 2025.